12 completed, 8 recruiting, 8 unknown, 4 terminated. 15 Phase 2, 14 Phase 1, 5 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Malignant Ascites: new trials by email Literature Review of Malignant Ascites trials Research Report on Malignant Ascites
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis) At-home Paracentesis - Malignant Ascites | Not applicable | Recruiting | University of Utah | 20 | 2026-09-15 | 2026-09-18 |
| TLR9 Immunotherapy for Peritoneal Carcinomatosis ACM-CpG - Malignant Ascites, Colorectal Adenocarcinoma | Phase 1 | Recruiting | Brown University | 24 | 2026-08-25 | 2026-10-01 |
| WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) WSK-IM02 - Advanced Solid Tumors, Malignant Pleural Effusions | Phase 1 | Not yet recruiting | WestVac Biopharma Co., Ltd. | 9 | 2026-06-01 | 2026-05-29 |
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| A Phase I Study of SIM0388 in Participants With Malignant Ascites. SIM0388 - Malignant Ascites | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 50 | 2025-04-24 | 2025-06-06 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody M701, paracentesis - Malignant Ascites | Phase 3 | Active not recruiting | Wuhan YZY Biopharma Co., Ltd. | 312 | 2024-03-25 | 2026-08-20 |
| Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Tocilizumab - Malignant Pleural Effusion, Malignant Ascites | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 12 | 2024-01-30 | 2025-05-22 |
| The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites serplulimab, Bevacizumab, rmhTNF-NC - Malignant Ascites | Phase 2 | Recruiting | Sun Yat-sen University | 60 | 2023-12-14 | 2024-05-30 |
| A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer T3011 - Malignant Ascites | Phase 1 | Unknown | West China Hospital | 10 | 2023-09-28 | 2024-01-11 |
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases Dual-targeting VEGFR1/PD-L1 CAR-T cells - Malignant Peritoneal Effusion, Malignant Ascites | Phase 1 | Recruiting | Sichuan University | 40 | 2023-02-15 | 2026-08-13 |
| PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 40 | 2022-09-01 | 2022-08-15 |
| Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody M701, paracentesis - Malignant Ascites | Phase 2 | Completed | Wuhan YZY Biopharma Co., Ltd. | 115 | 2021-11-24 | 2026-06-17 |
| Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites Nivolumab, Pembrolizumab - Malignant Ascites | Not applicable | Enrolling by invitation | China Medical University Hospital | 30 | 2021-01-01 | 2023-08-24 |
| Malignant Ascites Alfapump® Study alfapump system - Malignant Ascites | Withdrawn | Sequana Medical N.V. | 2020-05-31 | 2020-08-10 | ||
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites SCB-313 - Malignant Ascites | Phase 1 | Completed | Sichuan Clover Biopharmaceuticals, Inc. | 13 | 2019-09-28 | 2022-05-06 |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites BSG-001 - Malignant Pleural Effusion, Malignant Ascites | Phase 1 / Phase 2 | Unknown | BioSyngen Pte Ltd | 58 | 2019-01-01 | 2018-11-08 |
| A Study of M701 (EpCAM and CD3) in Malignant Ascites Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701 - Malignant Ascites, Cancer | Phase 1 | Completed | Wuhan YZY Biopharma Co., Ltd. | 35 | 2018-09-30 | 2025-07-17 |
| EUS-Guided Drainage of Refractory Malignant Ascites EUS-Guided drainage - Malignant Ascites | Unknown | Hospital Universitario Virgen Macarena | 100 | 2018-09-01 | 2018-06-08 |
Showing 20 of 40. Sign in to see all of them.
Pleural Effusion, Malignant (8) · Ascites (4) · Neoplasms (4) · Ovarian Neoplasms (4) · Carcinoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Peritoneal Neoplasms (2) · Adenocarcinoma, Mucinous (1) · Anus Neoplasms (1) · Appendiceal Neoplasms (1) · Breast Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Ductal (1)
Neoplasms by Site (16) · Neoplasms (15) · Pleural Neoplasms (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Pleural Diseases (8) · Digestive System Diseases (7) · Neoplasms by Histologic Type (7) · Pleural Effusion (7) · Neoplasms, Glandular and Epithelial (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Adnexal Diseases (5) · Digestive System Neoplasms (5)
Paracentesis (5) · Bevacizumab (4) · catumaxomab (3) · ACM-001 COVID-19 vaccine (1) · Cisplatin (1) · Drug Therapy (1) · Etanidazole (1) · Immune Checkpoint Inhibitors (1) · Interviews as Topic (1) · Metformin (1) · Nivolumab (1) · Nutritional Status (1) · Prednisolone (1) · Quality of Life (1) · Vascular Access Devices (1)
Sequana Medical N.V. (4) · Neovii Biotech (3) · Wuhan YZY Biopharma Co., Ltd. (3) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · AIO-Studien-gGmbH (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Base Therapeutics (Shanghai) Co., Ltd. (1) · Baylor College of Medicine (1) · BioSyngen Pte Ltd (1) · Brown University (1) · Charite University, Berlin, Germany (1) · China Medical University Hospital (1) · Dong sheng Zhang (1) · Dongfang Hospital Beijing University of Chinese Medicine (1) · Eastern Regional Medical Center (1)
China (16) · United States (9) · Germany (6) · Switzerland (3) · United Kingdom (3) · Spain (2) · Australia (1) · Czechia (1) · France (1) · Italy (1) · Netherlands (1) · Poland (1) · Taiwan (1)
Jianming Xu, MD (2) · Andrea De Gottardi, MD (1) · Andrea De Gottardi, Privatdozent (1) · Anna Beck, MD (1) · Bo Huang, Ph.D (1) · Christina Fotopoulou, Ph.D (1) · Christina Fotopoulou, Prof, MD (1) · Florian Lordick, PD Dr. med. (1) · Jeroen Capel, MSc (1) · Jianming Xu (1) · Jonathan Berek, MD MMSc (1) · Karin Jordan, Dr. med. (1) · Khaldoun Almhanna, MD (1) · Klaus Pietzner, MD (1)
PMID 12046997, PMID 16434188, PMID 22734013, PMID 25254563, PMID 25434633, PMID 25596153, PMID 26049121, PMID 28442933, PMID 28940225, PMID 31805921, PMID 35686702, PMID 41369826
P01CA087971 (1)